{"nctId":"NCT01662492","briefTitle":"A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine","startDateStruct":{"date":"2012-10"},"conditions":["Migraine Disorders"],"count":125,"armGroups":[{"label":"Botulinum toxin type A Dose 1","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A Dose 1"]},{"label":"Botulinum toxin type A Dose 2","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A Dose 2"]},{"label":"Placebo (Normal Saline)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (Normal Saline)"]}],"interventions":[{"name":"Botulinum toxin type A Dose 1","otherNames":["onabotulinumtoxinA","BOTOX®"]},{"name":"Botulinum toxin type A Dose 2","otherNames":["onabotulinumtoxinA","BOTOX®"]},{"name":"Placebo (Normal Saline)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Medical history of chronic migraine for at least 6 months\n* 15 or more headache days during a 4 week period\n\nExclusion Criteria:\n\n* Previous use of any botulinum toxin of any serotype for any reason\n* Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis\n* Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks prior to the week -4 screening visit\n* Use of any headache prophylaxis medication within 4 weeks prior to the week -4 screening visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Frequency of Headache Days","description":"Change from baseline in the frequency of headache days during the 28-day period, ending with Week 12 in the Intent-to-Treat population. A headache day for a patient is defined as a calendar day with 1 or more total hours of headache as recorded by the patient in the electronic diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"4.4"},{"groupId":"OG001","value":"23.4","spread":"4.8"},{"groupId":"OG002","value":"25.3","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"7.0"},{"groupId":"OG001","value":"-6.4","spread":"7.8"},{"groupId":"OG002","value":"-6.8","spread":"8.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Frequency of Severe Headache Days","description":"Change from baseline in the frequency of severe headache days during the 28-day period, ending with Week 12 in the Intent-to-Treat population. A severe headache day is defined as a calendar day with 1 or more total hours of headache and with maximum severity reported as 'severe' for the day as recorded by the patient in the electronic diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"5.0"},{"groupId":"OG001","value":"7.8","spread":"6.2"},{"groupId":"OG002","value":"9.1","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"4.7"},{"groupId":"OG001","value":"-2.3","spread":"6.3"},{"groupId":"OG002","value":"-0.9","spread":"7.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Total Cumulative Hours of Headache on Headache Days","description":"Change From Baseline in the Total Cumulative Hours of Headache on Headache Days during the 28-day period ending with Week 12 in the Intent-to-Treat Population. Total cumulative hours is defined as the sum of total duration of headaches on headache days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.69","spread":"151.60"},{"groupId":"OG001","value":"175.98","spread":"139.76"},{"groupId":"OG002","value":"212.68","spread":"184.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.52","spread":"53.19"},{"groupId":"OG001","value":"-19.03","spread":"113.73"},{"groupId":"OG002","value":"-50.04","spread":"87.36"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With ≥ 50% Decrease From Baseline in the Frequency of Headache Days","description":"Percentage of patients with ≥ 50% decrease from baseline in the frequency of headache days during the 28-day period ending with Week 12 in the Intent-to-Treat Population. A responder for headache days was defined as a patient with a 50% decrease in change from baseline in the frequency of headache days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"32.6","spread":null},{"groupId":"OG002","value":"29.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Are Prescribed Oral Rescue Migraine Prophylactic Treatment","description":"Percentage of patients who are prescribed oral rescue migraine prophylactic treatment during the 28-day period ending with Week 12 in the Intent-to-Treat population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"9.3","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":43},"commonTop":["Neck Pain","Upper Respiratory Tract Infection","Migraine","Musculoskeletal Pain","Dizziness"]}}}